Alebund Pharmaceuticals Receives FDA IND Clearance For AP308 In IgA Nephropathy

Alebund Pharmaceuticals (09637.HK) received FDA clearance for the IND application for AP308, an engineered recombinant IgA protease for IgA nephropathy. The clearance enables the company to begin U.S. clinical development of the investigational therapy, representing a meaningful regulatory and pipeline milestone.